



International Journal of Preclinical & Pharmaceutical Research

Journal homepage: www.preclinicaljournal.com

Ethical Considerations in High-Cost Drug Development and Access

**Dr. Balasubramanian V^{1*}, Balamurugan D², Melbha Starlin Chellathurai³,
John Singh Russel E³, Samsudeen R⁴**

¹Professor, Head of Department, The school of Pharmacy, Joy University, Raja Nagar, Alaganeri- 627116, Vadakankulam, Tirunelveli district, Tamil Nadu, India.

²Professor, Department of Pharmaceutics, Sri Ram Nallamani Yadava College of Pharmacy, Tenkasi, Tamil Nadu, India.

³Assistant professor, School of Pharmacy, Joy University, Raja Nagar, Alaganeri- 627116, Vadakankulam, Tirunelveli district, Tamil Nadu, India.

⁴Associate professor, Department of Pharmaceutics, S. Thangapazham pharmacy college, Vasudevanallur, Tenkasi district, Tamil Nadu, India.

ABSTRACT

The contemporary therapeutics have significantly reversed itself with the high-priced medications, including biologics, gene therapies, and precision medicines, enabling the treatment of previously incurable conditions. However, these innovations have serious financial implications as well, which limits the pricing to a certain level, particularly due to the fact that not everyone can afford it in low- and middle-income nations. This review analyzes the complex forces that can contribute towards high drug development costs, such as long research and development (R&D) cycles, biotechnology and personalized medicine. It also critically evaluates ethical concerns to do with the affordability of these drugs including the principles of beneficence, justice, and autonomy. Economic and social impacts of high drug prices are also raised with the focus on the issue of overloading healthcare systems and exacerbating health disparities. The review provides strategic recommendations to address these issues which include the ethical pricing models, public-private collaboration, compulsory licensing, and disclosure of the R&D funds. It also talks about how the digital health technologies will be used to reduce the cost of development and make the high-cost therapies more affordable. The future perspective repeats the need to have an equity-based innovation system, in which, public health issues, technological advances, and worldwide collaborations facilitate medical findings to all people, regardless of their socioeconomic status and position. The middle ground as suggested in this review appears to be a progressive solution to the situation in the healthcare industry across the globe by encouraging innovation and equal access to the therapies required.

Key Words: High-cost medications, Biologics, Gene therapies, Precision medicine, Drug development costs.

INTRODUCTION

Background on High-Cost Drug Development

The development of high-cost drugs, including biologics, gene therapies, cell-based interventions, orphan drugs, and targeted precision medicines, has transformed modern therapeutics by enabling treatment of previously incurable conditions. However, these innovations arise from complex and resource-intensive processes involving advanced technologies, lengthy clinical trials, strict regulatory pathways, and high failure

rates. [1, 2] The rising dependence on specialized platforms such as monoclonal antibody engineering, CRISPR gene editing, and personalized oncology pipelines further escalates development costs. These scientific and structural challenges have contributed to a pharmaceutical landscape where breakthrough therapies are often priced at levels that restrict their accessibility, especially in low- and middle-income countries. Understanding the underlying dynamics of cost generation is essential for evaluating the ethical implications surrounding affordability, fairness, and global access. [3, 4]

Corresponding Author

Dr. Balasubramanian V

Email: pharamabala@gmail.com

Economic and Social Impact

The introduction of high-cost drugs significantly influences healthcare systems, patient outcomes, and societal equity. On the economic front, premium-priced therapies strain national health budgets, insurance systems, and out-of-pocket expenditures, often forcing difficult prioritization decisions for policymakers and healthcare providers. For patients, the financial burden may result in delayed treatment, non-adherence, or complete exclusion from life-saving options. Socially, the availability of high-cost medicines amplifies disparities between affluent and underserved populations, highlighting ethical concerns related to justice, distributive fairness, and the moral obligations of pharmaceutical companies and governments. [5–7] Moreover, pricing models linked to market exclusivity and limited competition exacerbate inequalities, prompting global debates on compulsory licensing, value-based pricing, and public–private responsibility in drug development [8–10].

Objective and Scope of the Review

This review aims to critically examine the ethical considerations associated with high-cost drug development and access. It explores the multidimensional factors driving therapeutic pricing, evaluates their implications for patients and healthcare systems, and analyzes ethical frameworks that guide decision-making in this domain [3,11,12]. The discussion encompasses themes such as innovation incentives versus affordability, global access disparities, transparency in pricing, and the role of governments, regulatory agencies, and industry stakeholders in ensuring equitable access. [12–14] By synthesizing current literature and emerging policy debates, the review seeks to provide a comprehensive understanding of ethical challenges and propose directions for more just and sustainable models of drug development and distribution.

The Drug Development Landscape Cost and Time of R&D

Drug development is a long, complex, and financially demanding process that often spans more than a decade from discovery to market approval. The average cost of developing a new drug—including preclinical research, clinical trials, regulatory submissions, and post-marketing commitments—can exceed several billion dollars. High attrition rates across development stages further contribute to expenditure, as only a small fraction of candidate molecules successfully transition from laboratory experiments to clinical use. [15, 16] The rigorous requirements for safety, efficacy, and quality demand extensive clinical testing, advanced manufacturing platforms, and sophisticated analytical systems. Additionally, compliance with global regulatory frameworks, such as those mandated by the FDA, EMA,

and ICH, increases timelines and costs. This prolonged investment cycle plays a major role in the pricing of newly approved therapies, particularly those developed for rare diseases or highly targeted medical conditions. [17–19]

Role of Biotechnology and Precision Medicine

Biotechnology has dramatically reshaped the drug development paradigm by enabling innovative therapeutic modalities such as monoclonal antibodies, cell-based interventions, antisense oligonucleotides, RNA therapeutics, and CRISPR-based gene editing. These technologies allow unprecedented specificity and biological sophistication, supporting the shift towards precision medicine, where treatments are tailored to individual genetic or molecular profiles. [20–22] Precision-focused platforms require advanced genomic screening, personalized diagnostics, and high-complexity manufacturing processes that elevate both scientific value and cost. While these approaches enhance therapeutic outcomes, they inherently challenge scalability and affordability. [23–25] As precision medicine expands, the ethical balance between technological innovation and equitable access becomes increasingly critical, especially for resource-limited healthcare systems.

Case Examples of High-Cost Therapies (e.g., Gene Therapy, Oncology)

Several breakthrough therapies illustrate the financial and ethical complexities of high-cost drug development. Gene therapies such as onasemnogene abeparvovec for spinal muscular atrophy and voretigene neparvovec for inherited retinal dystrophy represent major scientific advances but are priced in the million-dollar range due to their individualized manufacturing and long-term curative potential [26, 27]. In oncology, CAR-T cell therapies (e.g., tisagenlecleucel, axicabtagene ciloleucel) require personalized extraction, genetic modification, and reinfusion of patient immune cells, resulting in substantial manufacturing and clinical support costs. Targeted therapies for rare cancers, including ALK inhibitors or PARP inhibitors, also command high prices due to niche indications and extensive molecular characterization requirements [26, 28]. These cases highlight the tension between rewarding innovation and ensuring patient affordability, underscoring the ethical challenges central to discussions on high-cost drug accessibility.[29]

Ethical Frameworks and Principles Beneficence and non-maleficence

Beneficence obligates healthcare systems and pharmaceutical stakeholders to promote patient well-being, while non-maleficence requires avoidance of harm. In the context of high-cost drug development, these principles underscore the need to ensure that innovative

therapies genuinely improve patient outcomes without creating unintended harm through financial toxicity. [30, 31] Excessive pricing can indirectly harm patients by restricting access, delaying treatment, or forcing them into financial hardship. Similarly, prioritizing profit-driven innovation over public health needs may lead to inequitable resource allocation. Ethical drug development must therefore balance scientific advancement with patient welfare, ensuring that therapeutic benefits meaningfully outweigh both clinical and economic risks. [12, 32]

Justice and Equity

The principle of justice emphasizes fair distribution of healthcare resources, ensuring that individuals have equitable access to essential therapies regardless of socioeconomic status or geographic location. High-cost drugs challenge this ideal by creating disparities between wealthy and underserved populations, and between high-income and low-income countries. Structural inequities in insurance coverage, reimbursement systems, and market exclusivity further widen access gaps. [12] Ethical decision-making demands that policymakers, industry leaders, and regulatory bodies consider distributive fairness when determining pricing strategies, resource prioritization, and access policies. Initiatives such as tiered pricing, compulsory licensing, and expanded patient-assistance programs can support greater equity but require coordinated global commitment [33, 34].

Autonomy and Informed Consent

Respect for autonomy requires that patients make informed decisions regarding their treatment options. However, autonomy is compromised when patients cannot access high-cost therapies due to financial barriers or inadequate information about economic implications. Informed consent must extend beyond clinical risks and benefits to include transparent discussions about affordability, insurance limitations, and alternative therapeutic pathways. [35, 36] Ethical practice demands that clinicians provide unbiased, comprehensive information that empowers patients to make meaningful choices. Ensuring autonomy also involves supporting patient-centered strategies, shared decision-making, and transparent communication throughout the treatment pathway.[37]

Corporate Social Responsibility

Corporate social responsibility (CSR) in the pharmaceutical industry entails balancing commercial success with obligations toward public health, ethical innovation, and global well-being. As companies develop high-cost therapies, they carry moral responsibilities to ensure pricing strategies that reflect societal needs, not merely market potential. CSR extends to supporting

access programs, facilitating technology transfer, and investing in neglected diseases with limited commercial profitability. [38, 39] Responsible conduct also includes transparency in R&D costs, fair patent practices, and collaborations with governments and global health agencies to improve affordability. By integrating CSR into their operational models, pharmaceutical companies can align profit motives with broader ethical commitments to society. [11, 40]

Drug Pricing: Ethics vs. Economics

Factors Influencing Drug Prices

Drug pricing is determined by a complex interplay of scientific, economic, and regulatory variables. High R&D expenditures, clinical trial complexities, and long timelines significantly contribute to elevated launch prices. Manufacturing costs, particularly for biologics, gene therapies, and personalized medicines, are substantially higher than those for traditional small-molecule drugs [41]. Market exclusivity, patent protections, and limited competition allow companies to set premium prices to recover investment and maximize returns. Additionally, pricing is influenced by therapeutic value, disease prevalence, expected market size, reimbursement frameworks, and pricing strategies adopted by pharmaceutical firms. [12, 42] These interconnected factors collectively shape the final cost of high-value therapies, often resulting in prices beyond the reach of many patients and healthcare systems.

Transparency in Pricing Models

A major challenge in drug pricing is the lack of transparency across the pharmaceutical value chain. True R&D costs, manufacturing expenses, marketing investments, and profit margins are often undisclosed, making it difficult for policymakers, clinicians, and patients to evaluate the fairness of pricing decisions. [43, 44] Confidential agreements between manufacturers and insurers or government payers further obscure cost structures, limiting the ability to implement value-based pricing or negotiate equitable costs. Greater transparency would enable more informed decision-making, promote accountability, and support the development of pricing frameworks that reflect therapeutic value while protecting patient access. Ethical pricing requires openly communicating cost justifications and clarifying how prices align with societal benefit. [11]

Ethical Concerns in Profit-Driven Pricing

Profit-driven pricing models raise critical ethical issues, particularly when life-saving or essential medicines are priced beyond affordability. While pharmaceutical companies argue that high prices incentivize innovation, excessively profit-oriented strategies can jeopardize patient well-being and

undermine health equity. [45, 46] The prioritization of shareholder interests over public health may result in unjustifiable price hikes, reduced access to breakthrough therapies, and widening socioeconomic disparities. Ethical concerns also emerge when companies exploit monopolies created by patents or regulatory exclusivity. Balancing financial returns with societal responsibility is essential to ensure that innovation does not come at the cost of human suffering or healthcare inequality [46].

Price Discrimination Across Nations

Price discrimination—where drug prices differ across countries—is a common strategy used to manage global affordability and maximize market penetration.

High-income nations often bear the highest prices due to greater purchasing power, while lower-income countries may receive tiered or discounted pricing [3, 47]. Although differential pricing can enhance access in resource-limited settings, it also raises ethical concerns when disparities are unjustifiably large or when middle-income nations face disproportionately high costs despite limited healthcare budgets. Parallel trade, intellectual property constraints, and global trade agreements further complicate cross-national pricing structures. [48–50] Ethical implementation of price discrimination requires balancing commercial viability with global fairness, ensuring that pricing strategies do not perpetuate health inequities or restrict access to essential therapies. [3, 30]

Table 1: Key Factors and Ethical Implications in Drug Pricing Models

Section	Key Points	Ethical and Economic Implications
Factors Influencing Drug Prices	- High R&D costs, clinical trial complexities, and long timelines- Manufacturing costs for biologics and personalized medicines- Market exclusivity, patent protections- Therapeutic value, disease prevalence, and market size	- Prices set to recover investment and maximize returns- Pricing may exceed affordability, limiting access for patients and healthcare systems.
Transparency in Pricing Models	- Lack of transparency in R&D, manufacturing, marketing costs, and profit margins- Confidential agreements between manufacturers, insurers, and government payers	- Hinders informed decision-making- Reduces accountability- Ethical pricing requires clear communication of cost structures and societal benefit alignment.
Ethical Concerns in Profit-Driven Pricing	- Profit-driven models may jeopardize access to life-saving medicines- Excessive pricing can undermine health equity- Companies may exploit monopolies or exclusivity	- The focus on shareholder profit over patient access creates inequality- Prioritizing innovation over affordability can harm public health and increase disparities.
Price Discrimination Across Nations	- Price differences based on purchasing power in high- vs. low-income countries- Tiered or discounted pricing for low-income countries- Global trade agreements and intellectual property constraints	- Price disparities may be unethical if excessively large or unfair- Balancing affordability with market penetration and ensuring fair access in all countries remains challenging.




Figure 1: Drug Pricing Dynamics

Accessibility and Affordability

Global Access Gaps

Access to high-cost drugs remains uneven worldwide, reflecting disparities in healthcare infrastructure, national income levels, regulatory capacity, and procurement mechanisms. While patients in high-income countries may benefit from advanced therapies, those in low- and middle-income regions often face delayed approvals, inadequate supply chains, and limited insurance coverage. [51, 52] Patents and market exclusivity intensify these gaps by restricting competition from generics or biosimilars. Additionally, disparities arise from differences in diagnostic capacity, clinician awareness, and distribution networks, further limiting timely access to innovative treatments. The resulting global access gaps highlight the ethical challenge of ensuring equitable distribution of medical advancements across diverse socioeconomic and geographic settings.[53]

Insurance and Reimbursement Systems

Insurance coverage and reimbursement policies play a pivotal role in determining patient access to high-cost therapies. Public and private insurers evaluate clinical benefit, cost-effectiveness, and budget impact before approving coverage, often leading to strict eligibility criteria or step-therapy requirements [54]. Limitations in reimbursement may shift financial responsibility to patients, resulting in substantial out-of-pocket costs and reduced adherence. Fragmented insurance models, especially in countries without universal healthcare, exacerbate disparities between socio-economic groups. Effective reimbursement strategies must balance affordability, sustainability, and therapeutic value, ensuring that high-cost drugs do not create financial hardship for vulnerable populations. [30, 55]

Compassionate Use and Early Access Programs

Compassionate use and early access programs provide pathways for patients with severe or life-threatening conditions to obtain investigational or unaffordable approved therapies outside standard regulatory processes. These programs are essential when no alternative treatment exists, offering hope to patients who would otherwise be excluded from advanced care. [56, 57] However, ethical concerns arise regarding fairness in eligibility, lack of comprehensive safety data, and unequal availability across regions. While such programs reflect pharmaceutical companies' social responsibility, their consistency, transparency, and governance vary widely internationally. Strengthening regulatory oversight and establishing equitable selection criteria can enhance the ethical integrity of early access initiatives. [51,58,59]

Impact on Low- and Middle-Income Countries

Low- and middle-income countries (LMICs) face profound challenges in accessing high-cost drugs due to economic constraints, inadequate public health financing, and limited technological infrastructure. High medicine prices often consume disproportionate shares of national healthcare budgets, forcing governments to prioritize basic services over advanced therapeutic options [58–60]. Weak insurance coverage and heavy dependence on out-of-pocket payments further restrict access. Additionally, diagnostic limitations, shortages of skilled personnel, and inconsistent cold-chain systems hinder the delivery of complex biologics and gene therapies. These barriers contribute to widening global health inequities, highlighting the need for international collaboration, flexible pricing models, and technology-sharing initiatives to improve affordability and accessibility in LMICs. [53, 61]

Table 2: Global Accessibility and Affordability Challenges in High-Cost Drug Access

Section	Key Points	Ethical and Economic Implications
Global Access Gaps	- Uneven access to high-cost drugs due to disparities in healthcare infrastructure, income levels, and regulatory capacity - Delayed approvals and limited insurance in low- and middle-income countries (LMICs)	- Ethical challenge of ensuring equitable distribution of medical advancements across diverse socioeconomic and geographic settings.
Insurance and Reimbursement Systems	- Public and private insurers evaluate clinical benefit, cost-effectiveness, and budget impact - Strict eligibility criteria and out-of-pocket costs for patients	- Financial hardship for vulnerable populations due to high out-of-pocket costs - Disparities exacerbated by fragmented insurance models, particularly in countries without universal healthcare.
Compassionate Use and Early Access Programs	- Pathways for patients to access investigational or unaffordable therapies - Ethical concerns around fairness, eligibility, and inconsistent availability across regions	- Issues of fairness in eligibility and safety data transparency - Strengthening regulatory oversight and equitable selection criteria is crucial for ethical integrity.

Impact on Low- and Middle-Income Countries	- LMICs face economic constraints, inadequate public health financing, and limited technological infrastructure - High medicine prices consume national healthcare budgets	- Economic barriers and weak insurance coverage limit access to high-cost therapies - Need for international collaboration, flexible pricing models, and technology-sharing initiatives.
---	---	---




Figure 2: Global Access Gaps

Regulatory and Policy Perspectives WHO and National Policy Guidelines

The World Health Organization (WHO) plays a critical role in shaping global norms for access to essential medicines, including high-cost therapies. WHO guidelines emphasize equitable availability, rational pricing, and the integration of expensive treatments into national health systems based on cost-effectiveness and public health value. [52, 59, 62] National policies, such as essential medicines lists, health technology assessment (HTA) frameworks, and pharmaceutical pricing regulations, reflect these principles while addressing country-specific needs and budgetary constraints. Many nations have implemented policies for generic substitution, biosimilar adoption, pooled procurement, and price negotiation to improve affordability. However, the integration of high-cost advanced therapies—such as gene therapies and biologics—remains challenging due to limited regulatory readiness, financial constraints, and uneven policy adoption across regions [63].

Role of FDA, EMA, and CDSCO in Approvals

Major regulatory authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO), guide the approval and oversight of high-cost drugs. These agencies evaluate safety, efficacy, and quality through rigorous clinical and manufacturing standards [64, 65]. Accelerated pathways such as Breakthrough Therapy Designation, Accelerated Approval, and Conditional Marketing Authorization enable faster access to promising treatments for severe conditions. While these pathways support innovation, they raise ethical concerns regarding evidence robustness, post-marketing commitments, and pricing justifications for drugs approved on limited clinical data. Harmonization of regulatory standards and improved international collaboration remain essential for ensuring timely yet responsible access to advanced therapies worldwide [65, 66].

Orphan Drug Act and Priority Review Ethics

The Orphan Drug Act (ODA) and similar global frameworks provide incentives—such as tax credits, market exclusivity, and waived fees—to encourage development of therapies for rare diseases. While these policies have stimulated innovation, they also raise ethical concerns when companies use orphan status to command exceptionally high prices or expand indications beyond initial rare disease markets. Priority review programs similarly aim to expedite approval for drugs addressing unmet medical needs, but accelerated access can amplify pricing power and limit affordability. [67, 68] The ethical challenge lies in balancing legitimate incentives for innovation with safeguards against exploitation, ensuring that rare disease therapies remain accessible and reasonably priced.

Patent Laws and Market Exclusivity

Patent protections and market exclusivity are fundamental to pharmaceutical innovation, granting temporary monopolies that allow companies to recoup R&D investments. However, these protections also enable high prices by delaying generic or biosimilar competition. Practices such as “evergreening,” secondary patenting, and strategic exclusivity extensions can restrict access even when the therapeutic value does not justify prolonged monopolies. [69, 70] International agreements, including TRIPS (Trade-Related Aspects of Intellectual Property Rights), influence global patent norms but often disadvantage low- and middle-income countries, which face difficulties in negotiating compulsory licensing or parallel importation. Achieving ethical balance requires reforms that encourage innovation while promoting timely access to affordable alternatives, particularly for life-saving therapies.

Role of Stakeholders

Pharmaceutical Industry Ethics

The pharmaceutical industry plays a central role in determining the accessibility and affordability of high-cost drugs. Ethical conduct requires balancing commercial objectives with social responsibility. While companies justify high prices as necessary to recover investment and fund future innovation, ethical concerns arise when pricing practices disproportionately prioritize profit over patient welfare. Responsible industry behavior includes transparent communication regarding R&D costs, equitable pricing strategies, participation in global access initiatives, and ensuring post-marketing surveillance to maintain safety and effectiveness. [71, 72] Companies are also expected to avoid exploitative practices such as evergreening patents or manipulating market exclusivity. Upholding ethical standards strengthens public trust and promotes sustainable innovation in the pharmaceutical sector.

Government and Public Health Systems

Governments and public health systems bear significant responsibility for regulating drug prices, ensuring equitable access, and safeguarding public interest. Policy tools such as price caps, reimbursement frameworks, national insurance schemes, and health technology assessments (HTA) help balance affordability and innovation. Governments also oversee procurement systems, promote competition through generic and biosimilar adoption, and negotiate pricing with manufacturers. [73] Effective governance requires transparency, interagency coordination, and evidence-based decision-making. In many countries, resource constraints challenge the integration of high-cost therapies into national programs, demanding strategic prioritization and flexible regulatory approaches. Public health systems must also focus on strengthening diagnostic capacity and healthcare infrastructure to support the safe delivery of advanced therapies.

Role of NGOs and Civil Society

Non-governmental organizations (NGOs) and civil society groups play a vital advocacy role in addressing disparities in access to high-cost drugs. They raise awareness about unmet patient needs, challenge unjustifiable pricing practices, and support policy reforms that promote equity. NGOs often facilitate procurement of essential medicines for marginalized populations, assist in capacity building, and contribute to global health initiatives such as vaccine access programs. Civil society engagement also ensures that patient voices are represented in policy debates, regulatory decisions, and drug development priorities. Their involvement adds essential transparency, accountability, and ethical oversight to the broader healthcare ecosystem [74, 75].

Media and Public Perception

The media significantly influences public perception of high-cost drugs, shaping debates on pricing, access, and pharmaceutical industry practices. Investigative reporting can expose unethical pricing strategies, highlight patient struggles, and hold stakeholders accountable. Conversely, sensationalized or incomplete information may distort public understanding, create unrealistic expectations, or fuel mistrust in regulatory systems. Responsible media coverage should balance scientific accuracy with social relevance, ensuring that discussions on therapeutic breakthroughs also address affordability and equity concerns. Moreover, public opinion—shaped through digital platforms, advocacy campaigns, and social media—can impact policy decisions, market behavior, and the prioritization of health issues [55].

Case Studies

Zolgensma (Gene Therapy)

Zolgensma, approved for spinal muscular atrophy (SMA), is one of the most expensive treatments globally, with a single-dose cost exceeding two million USD. Its high price reflects complex manufacturing using adeno-associated viral vectors, extensive clinical development, and the therapy's curative potential delivered through a one-time infusion. While Zolgensma represents a breakthrough in pediatric neuromuscular disease management, its extreme cost has triggered ethical debates around affordability, exclusivity, and the moral justification for pricing a life-saving therapy beyond the reach of many healthcare systems.[3] Limited global availability, constrained reimbursement pathways, and unequal access in low-resource regions underscore the larger ethical dilemma of balancing innovation with equitable treatment access.

Hepatitis C Antivirals

The introduction of direct-acting antivirals (DAAs), such as sofosbuvir, revolutionized treatment for hepatitis C, achieving cure rates above 90%. However, initial launch prices—often exceeding tens of thousands of dollars per course—created substantial financial barriers. Patents, limited competition, and high research investments contributed to these pricing decisions. Over time, licensing agreements and generic manufacturing significantly improved access in some low- and middle-income countries. [58, 76] Yet, disparities persist due to variable national policies, reimbursement restrictions, and intellectual property limitations. The case of DAAs highlights how targeted policy interventions and global licensing mechanisms can expand access, while also revealing the ethical tensions inherent in pricing curative therapies.

Cancer Immunotherapies (CAR-T)

Chimeric antigen receptor T-cell (CAR-T) therapies such as tisagenlecleucel and axicabtagene ciloleucel represent a paradigm shift in oncology, offering individualized treatment by genetically modifying a patient's T cells. Despite their clinical success in refractory leukemias and lymphomas, CAR-T therapies can cost several hundred thousand dollars per treatment. The costs largely arise from personalized manufacturing, complex hospital logistics, and intensive supportive care. Ethical concerns include unequal access between well-resourced and underserved hospitals, financial toxicity for patients, and controversies around reimbursement for therapies with uncertain long-term outcomes. [77, 78] CAR-T therapies demonstrate the profound challenge of integrating high-cost personalized medicine into existing healthcare financing models.

COVID-19 Vaccine Access and Licensing

The COVID-19 pandemic exposed major inequities in global vaccine distribution. While high-income countries secured early supplies of vaccines such as mRNA-based formulations, many low- and middle-income nations faced prolonged shortages. Intellectual property protections, limited manufacturing capacity, and supply chain dominance by a few companies intensified global disparities. Initiatives like COVAX attempted to promote equitable distribution, but challenges persisted due to vaccine nationalism and inadequate financing. Debates on patent waivers under the TRIPS agreement highlighted ethical questions about balancing innovation incentives with global public health needs. [14] The COVID-19 vaccine experience illustrates how licensing policies, manufacturing partnerships, and geopolitical dynamics can profoundly shape access to life-saving technologies.

Solutions and Strategic Approaches

Ethical Pricing Models

Ethical pricing models aim to balance innovation incentives with equitable patient access. Value-based pricing, where costs reflect clinical benefit and long-term outcomes, offers a more rational approach to determining drug prices. Differential or tiered pricing can help align costs with national income levels, ensuring broader global affordability. Outcome-based agreements—linking payment to therapeutic success—can reduce financial risks for healthcare systems while encouraging manufacturers to ensure real-world efficacy. Ethical pricing models must also avoid exploitation of monopolies, ensure fair profit margins, and incorporate societal considerations such as disease burden, unmet needs, and public investment in research.[24] Ultimately, these models seek to foster a sustainable balance between innovation and justice.

Public–Private Partnerships

Public–private partnerships (PPPs) play a crucial role in advancing research, promoting access to medicines, and bridging resource gaps in healthcare delivery. Collaborative ventures between governments, industry, academia, and global health organizations can support vaccine development, rare disease research, and capacity building in low-resource settings. PPPs facilitate shared risk, resource pooling, and knowledge exchange, enabling the development of therapies that may not be commercially viable under purely private models. Successful examples include global alliances for HIV, tuberculosis, and malaria, as well as initiatives supporting COVID-19 vaccines.[79] Ethical PPPs require transparency, accountability, and commitment to equitable outcomes, ensuring that public contributions result in accessible and affordable therapies.

Compulsory Licensing and Generic Access

Compulsory licensing allows governments to authorize generic production of patented medicines during public health emergencies or when prices are prohibitively high. This mechanism, supported under the TRIPS agreement, is a vital tool for improving access to essential medicines in low- and middle-income countries. Effective use of compulsory licensing has facilitated access to antiretroviral therapies, hepatitis C drugs, and COVID-19 treatments in several regions. [80, 81] However, its implementation often faces political pressure, trade disputes, and legal complexities. Strengthening national legal frameworks, improving local manufacturing capacity, and encouraging voluntary licensing agreements can enhance the ethical and practical impact of generic access strategies.

Transparent R&D Funding Disclosure

Transparent disclosure of research and development funding can address public concerns regarding unfair pricing. Much of the foundational research for high-cost therapies is supported by government grants, academic institutions, and public health agencies. Without clear visibility into the actual private-sector investment, it becomes difficult to justify elevated prices or claims of recouping R&D expenditure. Transparency enables more accurate cost-benefit evaluations, promotes accountability, and supports the development of fairer pricing frameworks [82]. Public disclosure also strengthens trust between manufacturers, regulators, and healthcare consumers, helping ensure that drug prices reflect genuine innovation costs rather than opaque commercial strategies.

Future Outlook

Toward Universal Health Coverage

The movement toward universal health coverage (UHC) represents a transformative pathway for improving access to high-cost drugs globally. UHC frameworks prioritize financial protection, equitable service delivery, and integration of essential therapies into national benefit packages. As countries expand insurance coverage and implement strategic purchasing mechanisms, the affordability of advanced therapeutics becomes more attainable. Multilateral collaborations, stronger regulatory harmonization, and global pooled procurement systems may further reduce cost disparities.[83] However, achieving UHC requires sustained political commitment, robust financing, and continuous strengthening of health systems. Incorporating high-cost but clinically valuable therapies into UHC policies will be critical for ensuring that breakthroughs in science translate into real-world benefits for all populations.

Role of AI and Digital Health in Cost Reduction

Artificial intelligence (AI) and digital health technologies have the potential to significantly reduce drug development and healthcare delivery costs. AI-driven drug discovery can accelerate target identification, optimize molecule design, and predict clinical outcomes, reducing both timelines and resource expenditure. Machine learning models can streamline clinical trial design, enhance patient recruitment, and improve safety monitoring. Digital therapeutics, telemedicine, and remote patient monitoring can reduce treatment costs by minimizing hospital visits and improving adherence. [84, 85] Furthermore, real-world evidence generated through digital platforms supports value-based pricing and more efficient regulatory decision-making. As these technologies mature, they may help lower development costs and improve global affordability of advanced therapies.

Equity-Focused Innovation Ecosystem

Building an innovation ecosystem centered on equity requires reimagining the traditional pharmaceutical development model. This approach emphasizes patient-centered research priorities, inclusive clinical trials, and collaborative innovation between public and private sectors. Encouraging open science, technology transfer, and local manufacturing capacity can strengthen global access to emerging therapies. Equity-focused ecosystems also promote affordability by integrating ethical pricing frameworks, transparent R&D funding, and active involvement of civil society in decision-making.[35] By aligning innovation with social justice, public health priorities, and global solidarity, such ecosystems can ensure that scientific advancements benefit populations across socioeconomic and geographic divides. This vision represents a sustainable and ethically grounded future for the development and delivery of high-cost medicines [3, 83, 86, 87].

CONCLUSION

Creating and making expensive drugs available is a difficult nexus of innovation, morality, and health equity in the world. With biologics, gene therapies, and precision medicines, pharmaceutical companies are pushing the limits of science, which makes the cost of these developments prohibitively expensive, particularly among low- and middle-income groups of the population. Not only do these high costs impose a burden on the financial resources of healthcare systems, they also increase the gap between those with and without access to global health, fueling the inequality gap in global health access. The debate on the balance between innovation and affordability is an ethical domain, which is informed by ethical frameworks like beneficence, justice, and autonomy to ensure that life-saving

treatments are not retained by the patients who require such treatment the most.

Ethical pricing models, public-private partnerships, compulsory licensing and open disclosure of R&D funding can be a good solution to drug accessibility issues. These strategies can be adopted to reduce the financial toxicity and establish a more equal access to the necessary treatments. Meanwhile, the technological changes in AI, digital health, and data-driven drug discovery can potentially reduce the development cost and enhance its efficiency, providing new avenues to make high-cost drugs more affordable.

Finally, the future of the expensive development and accessibility of drugs is the establishment of an improved, sustainable, and equity-oriented innovation ecosystem. This will involve cooperation among stakeholders, namely the pharmaceutical industry, governments, NGOs, and the civil society so that medical innovations are not only enjoyed by the rich but also by everyone irrespective of social economic factors and geographical barriers. These ethical and strategic solutions will need to be collectively committed to in order to have a more just and equitable health landscape across the globe, where high-priced medications will not only assist those who are wealthy in the community.

REFERENCES

1. Subbiah, V., Othus, M., Palma, J., Cuglievan, B., & Kurzrock, R. Designing clinical trials for patients with rare cancers: Connecting the zebras. *American Society of Clinical Oncology Educational Book*, 45, 2025.
2. Da Silva Barreto, G., Lucas Ferreira Luz Da Silva, S., Cristina Santos De Almeida, K., Carlos Marcolino Neto, J., & Brito Do Nascimento, J. CRISPR therapy: A revolutionary breakthrough in genetic medicine. *International Healthcare Review*, 2024.
3. Tfayli, A. H., El-Halabi, L. N., & Khuri, F. R. Global disparities in cancer care: Bridging the gap in affordability and access to medications between high and low-income countries. *Cancer*, 131, 2024.
4. Ibrahim, A. M., & Jahanfar, S. Effectiveness and equity of mHealth apps for preeclampsia management in LMICs: A rapid review protocol. *PLOS ONE*, 19, 2024, e0313655.
5. Ragavan, M. V., Swartz, S., Chino, F., & Clark, M. Pharmacy assistance programs for oral anticancer drugs: A narrative review. *JCO Oncology Practice*, 20, 2024, 472–482.
6. Jönsson, L., Wimo, A., Handels, R., Johansson, G., Boada, M., Engelborghs, S., et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: An EADC-EC viewpoint. *The Lancet Regional Health - Europe*, 29, 2023, 100657.
7. Mingge, X., Zhe, Z., Qi, L., Jingyu, W., & Qing, R. Promoting access to innovative anticancer medicines: A review of drug price and national reimbursement negotiation in China. *INQUIRY*, 60, 2023, 004695802311707.
8. Rea, D., Froehle, C., Fermann, G., Pancioli, A., Masterson, S., & Stettler, B. Unequal but fair: Incorporating distributive justice in operational allocation models. *Production and Operations Management*, 30, 2021, 2304–2320.
9. Jafino, B. A., Kwakkel, J. H., & Taebi, B. Enabling assessment of distributive justice through models for climate change planning: A review of recent advances and a research agenda. *WIREs Climate Change*, 12, 2021.
10. Martin-Howard, S., & Farmbry, K. Framing a needed discourse on health disparities and social inequities: Drawing lessons from a pandemic. *Public Administration Review*, 80, 2020, 839–844.
11. Manders, E. A., Van Den Berg, S., De Visser, S. J., & Hollak, C. E. M. Drug pricing models, no 'one-size-fits-all' approach: A systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape. *European Journal of Health Economics*, 26, 2024, 683–696.
12. Vallano, A., & Pontes, C. Escalating costs of innovative medicines: Perspective and proposals. *Front Public Health*, 12, 2024.
13. Leighl, N. B., Ezeife, D. A., Nirmalakumar, S., & Gyawali, B. An arm and a leg: The rising cost of cancer drugs and impact on access. *American Society of Clinical Oncology Educational Book*, 41, 2021, e1–e12.
14. Santangelo, O. E., Provenzano, S., Di Martino, G., & Ferrara, P. COVID-19 vaccination and public health: Addressing global, regional, and within-country inequalities. *Vaccines*, 12, 2024, 885.
15. Franco, P., Jain, R., Hey, C., Koban, M. U., & Rosenkrands-Lange, E. Regulatory pathways supporting expedited drug development and approval in ICH member countries. *Therapeutic Innovation & Regulatory Science*, 57, 2022, 484–514.
16. Wang, Y., & Grainger, D. W. Regulatory considerations specific to liposome drug development as complex drug products. *Frontiers in Drug Delivery*, 2, 2022, 901281.
17. Amaral, C., Bell, V., Veiga, F., Rodrigues, A. R., Paiva, M. Global regulatory challenges for medical devices: Impact on innovation and market access. *Applied Sciences*, 14, 2024, 9304.
18. Giorgioni, L., Ambrosone, A., Cometa, M. F., Salvati, A. L., Nisticò, R., & Magrelli, A. Revolutionizing CAR T-cell therapies: Innovations in genetic engineering and manufacturing to enhance efficacy and accessibility. *International Journal of Molecular Sciences*, 25, 2024, 10365.
19. Mishra, S., & Venkatesh, M. Rare disease clinical trials in the European Union: Navigating regulatory and clinical challenges. *Orphanet Journal of Rare Diseases*, 19, 2024.

20. Samanta, D. Precision therapeutics in Lennox-Gastaut syndrome: Targeting molecular pathophysiology in a developmental and epileptic encephalopathy. *Children*, 12, 2025, 481.
21. Udeabor, S. Monoclonal antibodies in modern medicine: Their therapeutic potential and future directions. *Therapeutic Products*, 2, 2024, 12–20.
22. McDowall, S., Aung-Htut, M., Wilton, S., & Li, D. Antisense oligonucleotides and their applications in rare neurological diseases. *Frontiers in Neuroscience*, 18, 2024.
23. Evans, W., Qureshi, N., Kai, J., & Meslin, E. M. Precision medicine - Are we there yet? A narrative review of precision medicine's applicability in primary care. *Journal of Precision Medicine*, 14, 2024, 418.
24. Friebe, M., & Haider, S. Biomedical and healthtech innovation: The dilemma between purpose, current stakeholder economics, and patient benefits/desires — What might the future of health look like? 2024.
25. Maluleke, N. P. A call for linguistic and culturally congruent family-centred early hearing detection and intervention programmes in South Africa. *South African Journal of Communication Disorders*, 71, 2024.
26. Mehta, A., Motavaf, M., Nebo, I., Luyten, S., Osei-Opore, K. D., & Gru, A. A. Advancements in melanoma treatment: A review of PD-1 inhibitors, T-VEC, mRNA vaccines, and tumor-infiltrating lymphocyte therapy in an evolving landscape of immunotherapy. *Journal of Clinical Medicine*, 14, 2025, 1200.
27. Vakili-Ojaroood, M., Naseri, A., Shirinzadeh-Dastgiri, A., Saberi, A., Haghighikhan, S. M., Rahmani, A., et al. Ethical considerations and equipoise in cancer surgery. *Indian Journal of Surgery Oncology*, 15, 2024, 363–373.
28. Rueda, J., De Miguel Beriain, I., & Montoliu, L. Affordable pricing of CRISPR treatments is a pressing ethical imperative. *The CRISPR Journal*, 7, 2024, 220–226.
29. Bondar, D., & Karpichev, Y. Poly(ADP-Ribose) polymerase (PARP) inhibitors for cancer therapy: Advances, challenges, and future directions. *Biomolecules*, 14, 2024, 1269.
30. Burisch, J., Claytor, J., Hernandez, I., Hou, J. K., & Kaplan, G. G. The cost of inflammatory bowel disease care – How to make it sustainable. *Clinical Gastroenterology and Hepatology*, 23, 2024, 386–395.
31. Wang, Y., Ji, Q., Luo, B., Wang, X., & Cao, X. Financial toxicity, coping strategies, and quality of life among Chinese patients with hematologic malignancies: A cross-sectional study. *Supportive Care in Cancer*, 32, 2024.
32. Ye, P., Ye, Z., Xia, J., Zhong, L., Zhang, M., Lv, L., et al. National-scale 1-km maps of hospital travel time and hospital accessibility in China. *Scientific Data*, 11, 2024.
33. Khan, M. S., Umer, H., & Faruque, F. Artificial intelligence for low-income countries. *Humanities and Social Sciences Communications*, 11, 2024.
34. Mansfield, B. S., Mohamed, F., Larouche, M., Raal, F. J. The hurdle of access to emerging therapies and potential solutions in the management of dyslipidemias. *Journal of Clinical Medicine*, 13, 2024, 4160.
35. Weiner, E. B., Dankwa-Mullan, I., Nelson, W. A., & Hassanpour, S. Ethical challenges and evolving strategies in the integration of artificial intelligence into clinical practice. *PLOS Digital Health*, 4, 2025, e0000810.
36. Goktas, P., & Grzybowski, A. Shaping the future of healthcare: Ethical clinical challenges and pathways to trustworthy AI. *Journal of Clinical Medicine*, 14, 2025, 1605.
37. Ehidiemen, A., & Oladapo, O. Enhancing ethical standards in clinical trials: A deep dive into regulatory compliance, informed consent, and participant rights protection frameworks. *World Journal of Bio Pharmacy and Health Sciences*, 20, 2024, 309–320.
38. Srivastava, V. Impact of corporate social responsibility (CSR) initiatives on brand reputation: A study on how CSR activities enhance brand reputation and consumer loyalty in the context of sustainable marketing practices. *International Journal of Scientific Research and Applications*, 13, 2024, 1910–1930.
39. Indarto, S. L., Asmara, G. Y. P., & Purwoko, A. J. The role of corporate social responsibility in supporting SDGs: A propriety and fairness perspective. *Journal of Law and Social Development and Governance Review*, 5, 2024, e02794.
40. Huang, C., & Li, Z. The role of cross-border alliances in corporate social responsibility: International evidence. *Journal of Financial Research*, 47, 2024, 823–875.
41. Laichapis, M., Sakulbumrungsil, R., Udomaksorn, K., Kessomboon, N., Nerapusee, O., Hongthong, C., et al. Financial feasibility of developing sustained-release incrementally modified drugs in Thailand's pharmaceutical industry: Mixed methods study. *JMIRx Med*, 6, 2025, e65978.
42. Horrow, C., & Kesselheim, A. S. Confronting high costs and clinical uncertainty: Innovative payment models for gene therapies. *Health Affairs*, 42, 2023, 1532–1540.
43. Simoens, S., & Toumi, M. Drug pricing and transparency in Europe and the United States: What is it and how does it work? *Expert Review of Pharmacoeconomics & Outcomes Research*, 24, 2024, 477–486.
44. Adeusi, K., Jejenywa, T., & Jejenywa, T. Advancing financial transparency and ethical governance: Innovative cost management and accountability in higher education and industry. *International Journal of Management and Entrepreneurship Research*, 6, 2024, 1533–1546.

45. Kliegman, M., Zaghlula, M., Abrahamson, S., Esensten, J. H., Wilson, R. C., Urnov, F. D., et al. A roadmap for affordable genetic medicines. *Nature*, 634, 2024, 307–314.
46. Nagel, K. E., Ramachandran, R., & Lipska, K. J. Lessons from insulin: Policy prescriptions for affordable diabetes and obesity medications. *Diabetes Care*, 47, 2024, 1246–1256.
47. Shahvaroughi Farahani, M., & Ghasemi, G. Artificial Intelligence and Inequality: Challenges and Opportunities. *Qeios*, 2024.
48. Piccoli, L., & Perna, R. Civil society organisations and the healthcare of irregular migrants: the humanitarianism-equity dilemma. *CMS*, 2024.
49. Such, E., Smith, K., Woods, H. B., Meier, P. Governance of Intersectoral Collaborations for Population Health and to Reduce Health Inequalities in High-Income Countries: A Complexity-Informed Systematic Review. *Int J Health Policy Manag*, 2022.
50. Destigter, K., Pool, K-L., Leslie, A., Hussain, S., Tan, B. S., Donoso-Bach, L., et al. Optimizing integrated imaging service delivery by tier in low-resource health systems. *Insights Imaging*, 2021.
51. Malhotra, S., Cameron, A-I., Gotham, D., Burrone, E., Gardner, P. J., Loynachan, C., et al. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries. *PLOS Global Public Health*, 2024.
52. Li, C., Spencer, G., Husain, M. J., Nugent, R., Auzenne, D., Kostova, D., et al. Barriers to accessibility of medicines for hyperlipidemia in low- and middle-income countries. *PLOS Global Public Health*, 2024.
53. Alupo, P., Baluku, J., Bongomin, F., Siddharthan, T., Katagira, W., Ddungu, A., et al. Overcoming challenges of managing chronic obstructive pulmonary disease in low- and middle-income countries. *Expert Review of Respiratory Medicine*, 2024.
54. Gilchrist, A., Fernando, G. V. M. C., Holland, P., Ahmed, F. Factors affecting women's access to primary care in the United States since the Affordable Care Act: A mixed-methods systematic review. *PLoS ONE*, 2024.
55. Ng, Q. X., Ong, C., Chan, K. E., Ong, T. S. K., Lim, I. J. X., Tang, A. S. P., et al. Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review. *Health Econ Rev*, 2024.
56. Ali, H. I., Othman, A. A., Atta, M. H. R., Mohamed, S. S., Mohamed, S. H. Revelation of the mediation role of moral sensitivity on safety attitude and personality traits among critical care nurses. *BMC Nursing*, 2025.
57. Webb, J., Shah, L. D., Lynch, H. F. Ethically Allocating COVID-19 Drugs Via Pre-approval Access and Emergency Use Authorization. *The American Journal of Bioethics*, 2020.
58. Bamodu, O. A., & Chung, C-C. Cancer Care Disparities: Overcoming Barriers to Cancer Control in Low- and Middle-Income Countries. *JCO Global Oncology*, 2024.
59. Ombelet, W., & Lopes, F. FERTILITY CARE IN LOW AND MIDDLE INCOME COUNTRIES: Fertility care in low- and middle-income countries. *Reproduction & Fertility*, 2024.
60. Perry, H. B., & Sachs, J. D. The Investment Case for Strengthening Primary Healthcare and Community Health Worker Programs in Low- and Lower-Middle-Income Countries, 2024.
61. Jones-Esan, L., Somasiri, N., & Lorne, K. Enhancing Healthcare Delivery Through Digital Health Interventions: A Systematic Review on Telemedicine and Mobile Health Applications in Low and Middle-Income Countries (LMICs), 2024.
62. Stolbrink, M., Ozoh, O. B., Halpin, D. M. G., Nightingale, R., Meghji, J., Plum, C., et al. Availability, cost and affordability of essential medicines for chronic respiratory diseases in low-income and middle-income countries: a cross-sectional study. *Thorax*, 2024.
63. Mishra, S., Bhat, D., & Venkatesh, M. Navigating health policies and programs in India: exploring opportunities to improve rare disease management and orphan drug research. *Orphanet J Rare Dis*, 2024.
64. Hakariya, H., Moriarty, F., Ozaki, A., Mulinari, S., Saito, H., Tanimoto, T. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals. *Clinical Translational Science*, 2024.
65. Brown, D. G. A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs. *J Med Chem*, 2024.
66. Chow, S. C., Chow, S. S., & Pong, A. Novel Design and Analysis for Rare Disease Drug Development. *Mathematics*, 2024.
67. Yadav, P., Kedar, A. S., Yadav, P. K., Gayen, J. R., Shah, A. A., Tiwari, A. K., et al. Development and approval of novel injectables: enhancing therapeutic innovations. *Expert Opinion on Drug Delivery*, 2024.
68. Michaeli, T., & Michaeli, D. T. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending. *Value in Health*, 2024.
69. Mucke, H. A. M. International Drug Repurposing Patent Landscaping, Part 1: Rare Diseases 2010–2023. *Drug Repurposing*, 2024.
70. Carl, D. L., Laube, Y., Serra-Burriel, M., Naci, H., Ludwig, W-D., Vokinger, K. N. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland. *JAMA Netw Open*, 2022.

71. Kanyamukenge, C. I., & Kagwaini, D. M. Role of Ethical Leadership in Promoting Sustainable Business Practices. *IJBM*, 2024.
72. Harishbhai Tilala, M., Saoji, R., Kumar Chenchala, P., Naguri, S., Kaur, J., Choppadandi, A., et al. Ethical Considerations in the Use of Artificial Intelligence and Machine Learning in Health Care: A Comprehensive Review. *Cureus*, 2024.
73. Drummond, M., Rutten, F., Jönsson, B., Stargardt, T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. *Eur J Health Econ*, 2010.
74. Rigolon, A., Osei Owusu, R., Leslie, J., Viera, S., Romero, F., Espiricueta, A. Non-governmental organizations, green space equity, and policy change: A national study in the US. *Urban Forestry & Urban Greening*, 2024.
75. Nunes, C., McKee, M., & Howard, N. The role of global health partnerships in vaccine equity: A scoping review. *PLOS Glob Public Health*, 2024.
76. Pain, D., Macduffie, E., Martei, Y. M., Kassick, M., Ikeda, D. J., Shulman, L. N., et al. Barriers to Implementing a Quality Improvement Program in Low- and Middle-Income Countries: Adequacy of Resources. *JCO Glob Oncol*, 2024.
77. Sainatham, C., Yadav, D., Dilli Babu, A., Tallapalli, J. R., Kanagala, S. G., Filippov, E., et al. The current socioeconomic and regulatory landscape of immune effector cell therapies. *Front Med*, 2024.
78. Mishra, H. K., & Kalyuzhny, A. Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology. *Cells*, 2024.
79. Abdul, S., Udedeh, E., Adeghe, E., Adegoke, A., Adegoke, B. Public-private partnerships in health sector innovation: Lessons from around the world. *Magna Sci Adv Biol Pharm*, 2024.
80. Tenni, B., Moir, H. V. J., Townsend, B., Kilic, B., Farrell, A-M., Keegel, T., et al. What is the impact of intellectual property rules on access to medicines? A systematic review. *Global Health*, 2022.
81. Motari, M., Nikiema, J-B., Tumusiime, P., Loua, A., Kasilo, O. M. J., Sougou, A., et al. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement. *BMC Public Health*, 2021.
82. Abulibdeh, R., Celi, L. A., Sejdić, E. The illusion of safety: A report to the FDA on AI healthcare product approvals. *PLOS Digit Health*, 2025.
83. Forslund, M., Mathieson, K., Djibo, Y., Mbindyo, C., Lugangira, N., Balasubramaniam, P. Strengthening the evidence base on the use of digital health technologies to accelerate progress towards universal health coverage. *Oxford Open Digital Health*, 2024.
84. Omidian, H. AI-powered breakthroughs in material science and biomedical polymers. *Journal of Bioactive and Compatible Polymers*, 2024.
85. Arefin, S., & Simcox, M. AI-Driven Solutions for Safeguarding Healthcare Data: Innovations in Cybersecurity. *IBR*, 2024.
86. Kumar, P., Sharma, N. C., & Sharma, L. Sustainable Development Balancing Economic Viability, Environmental Protection, and Social Equity. *IGI Global*, 2024, p. 212–234.
87. Chen, V., & Shao, W. Balancing medical innovation and affordability in the new healthcare ecosystem in China: Review of pharmaceutical pricing and reimbursement policies. *Health Care Science*, 2023.